{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001470","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.604621+00:00","generated_at":"2026-06-22T11:54:43.361970+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M","bullets":["Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).","DSA segment revenue $619.5M (+16.5%) drove results; Manufacturing declined -1.7% to $189.6M.","Narrows 2022 guidance: reported revenue growth 10-11%, non-GAAP EPS $10.80-10.95 (prior $10.70-10.95).","Announced divestiture of Avian Vaccine business for ~$170M cash plus up to $30M contingent; close expected by year-end.","Divestiture to reduce 2023 revenue by ~$80M and non-GAAP EPS by ~$0.35 before redeployment of proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001470","json":"https://secwatch.observer/filing/0001157523-22-001470.json","markdown":"https://secwatch.observer/filing/0001157523-22-001470.md","text":"https://secwatch.observer/filing/0001157523-22-001470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/0001157523-22-001470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/a52958171.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:54:43.361970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d9a5b0bdae2b1778848efb32f2131ef1d91ccca","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported third quarter ended September 24, 2022 results: revenue $989.2 million, net income $96.5 million, EPS $1.88. Guidance reaffirmed.","evidence_excerpt":"EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a52958171ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results – Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces Planned","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/0001157523-22-001470-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 24, 2022"},{"label":"Revenue","value":"$989.2 million"},{"label":"Net income","value":"$96.5 million"},{"label":"EPS","value":"$1.88"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}